George, D. J., Hessel, C., Halabi, S., Michaelson, M. D., Hahn, O., Walsh, M., . . . Choueiri, T. K. (2019). Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist.
Chicago Style citaatGeorge, Daniel J., et al. "Cabozantinib Versus Sunitinib for Untreated Patients With Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN Trial." Oncologist 2019.
MLA citatieGeorge, Daniel J., et al. "Cabozantinib Versus Sunitinib for Untreated Patients With Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN Trial." Oncologist 2019.